Maximiliano Ramia de Cap, Leo P Wu, Christian Hirt, German A Pihan, Sanjay S Patel, Wayne Tam, Carlos E Bueso-Ramos, Rashmi Kanagal-Shamanna, Philipp W Raess, Alexa Siddon, Damodaran Narayanan, Elizabeth A Morgan, Geraldine S Pinkus, Emily F Mason, Eric D Hsi, Heesun J Rogers, Laura Toth, Kathryn Foucar, Stephanie N Hurwitz, Adam Bagg, Anton Rets, Tracy I George, Attilio Orazi, Daniel A Arber, Robert P Hasserjian, Olga K Weinberg
Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with NPM1 mutation to 106 AML with NPM1 mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype ( p = .009 and p = .007, respectively) and was enriched in mutations of genes involved in histone modification, including ASXL1 ( p = ...
March 24, 2023: Leukemia & Lymphoma